DE69836346T2 - Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer - Google Patents

Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer Download PDF

Info

Publication number
DE69836346T2
DE69836346T2 DE69836346T DE69836346T DE69836346T2 DE 69836346 T2 DE69836346 T2 DE 69836346T2 DE 69836346 T DE69836346 T DE 69836346T DE 69836346 T DE69836346 T DE 69836346T DE 69836346 T2 DE69836346 T2 DE 69836346T2
Authority
DE
Germany
Prior art keywords
methyl
amino
alkyl
aminocarbonylmethyl
pyridinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69836346T
Other languages
German (de)
English (en)
Other versions
DE69836346D1 (de
Inventor
Tianbao Collegeville LU
E. Bruce Collegeville TOMCZUK
P. Thomas Morgantown MARKOTAN
Colleen Kennett Square SIEDEM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of DE69836346D1 publication Critical patent/DE69836346D1/de
Application granted granted Critical
Publication of DE69836346T2 publication Critical patent/DE69836346T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
DE69836346T 1997-11-26 1998-11-25 Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer Expired - Fee Related DE69836346T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6647597P 1997-11-26 1997-11-26
US66475P 1997-11-26
US6732497P 1997-12-05 1997-12-05
US67324P 1997-12-05
US7910798P 1998-03-23 1998-03-23
US79107P 1998-03-23
PCT/US1998/025185 WO1999026926A1 (en) 1997-11-26 1998-11-25 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Publications (2)

Publication Number Publication Date
DE69836346D1 DE69836346D1 (de) 2006-12-14
DE69836346T2 true DE69836346T2 (de) 2007-05-24

Family

ID=27370979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836346T Expired - Fee Related DE69836346T2 (de) 1997-11-26 1998-11-25 Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer

Country Status (14)

Country Link
US (8) US6037356A (US06566379-20030520-C00036.png)
EP (1) EP1036063B1 (US06566379-20030520-C00036.png)
JP (1) JP2001524467A (US06566379-20030520-C00036.png)
AR (1) AR016702A1 (US06566379-20030520-C00036.png)
AT (1) ATE344246T1 (US06566379-20030520-C00036.png)
AU (1) AU751412B2 (US06566379-20030520-C00036.png)
BR (1) BR9815325A (US06566379-20030520-C00036.png)
CA (1) CA2311969A1 (US06566379-20030520-C00036.png)
DE (1) DE69836346T2 (US06566379-20030520-C00036.png)
EA (1) EA004180B1 (US06566379-20030520-C00036.png)
ES (1) ES2274587T3 (US06566379-20030520-C00036.png)
PL (1) PL340560A1 (US06566379-20030520-C00036.png)
TW (1) TWI222441B (US06566379-20030520-C00036.png)
WO (1) WO1999026926A1 (US06566379-20030520-C00036.png)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751412B2 (en) * 1997-11-26 2002-08-15 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
EP1073449A4 (en) * 1998-04-24 2003-01-02 Dimensional Pharm Inc AMINO ACID AMIDINOHYDRAZONES, ALCOXYGUANIDINES AND AMINOGUANIDINES FOR USE AS ENZYME PROTEASE INHIBITORS
DE69942159D1 (de) * 1998-06-11 2010-04-29 Ortho Mcneil Pharm Inc Pyrazine Protease Inhibitore
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AU771928B2 (en) * 1999-05-19 2004-04-08 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) * 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6906068B1 (en) 1999-05-19 2005-06-14 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants
US6908919B2 (en) * 1999-05-19 2005-06-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
MXPA01011956A (es) 1999-05-27 2002-06-21 Dimensional Pharm Inc Oxazaheterociclos como inhibidores de proteasas.
DE60005351D1 (de) 1999-07-09 2003-10-23 Dimensional Pharm Inc Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel
DK1212300T3 (da) 1999-09-13 2004-03-15 Dimensional Pharm Inc Azacyclololalkanonserinproteaseinhibitorer
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
ATE289299T1 (de) * 2000-04-05 2005-03-15 Pharmacia Corp Polyzyclisch aryl und heteroaryl substituierte 4- pyronen verwendbar als selektive hemmung von dem koagulationsprozess
US20040171616A9 (en) * 2000-04-17 2004-09-02 South Michael S. Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
WO2001087842A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
KR20030015393A (ko) 2000-07-17 2003-02-20 3-디멘져널 파마슈티칼즈 인코오포레이티드 프로테아제 억제제 기능이 있는 시클릭 옥시구아니딘피라지논
AU2001277242A1 (en) 2000-08-04 2002-02-18 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US20030236257A1 (en) * 2001-04-04 2003-12-25 South Michael S. Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the cogulation cascade
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
CA2462647A1 (en) * 2001-10-03 2003-04-10 Michael S. South 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
BR0213092A (pt) * 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
WO2003093242A2 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7262211B2 (en) 2001-12-04 2007-08-28 Dendreon Corporation Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
JP4744149B2 (ja) 2002-12-03 2011-08-10 ファーマサイクリックス インコーポレイテッド 第ｖｉｉａ因子阻害剤としての２−（２−ヒドロキシビフェニル−３−イル）−１ｈ−ベンゾイミダゾール−５−カルボキサミジン誘導体
ATE432703T1 (de) * 2003-04-10 2009-06-15 Ortho Mcneil Pharm Inc Substituierte phenylacetamide und ihre anwendung als protease inhibitoren
WO2005110988A1 (en) * 2004-05-07 2005-11-24 Janssen Pharmaceutica, N.V. Pyridone compounds as inhibitors of bacterial type iii protein secretion systems
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
US20070255177A1 (en) * 2006-04-27 2007-11-01 Pronovost Allan D Devices and methods for collecting oral samples of enriched serous fluid
US7758001B2 (en) * 2006-09-13 2010-07-20 Premier Mounts Mount with magnetic attachment and automatic safety latching
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
NZ581606A (en) 2007-05-03 2012-06-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
ES2408159T3 (es) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
EP3018481B1 (en) 2009-05-20 2018-02-21 Sekisui Medical Co., Ltd. Blood coagulation time prolonging agent
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
US8349832B2 (en) * 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
AU2011349022B2 (en) 2010-12-21 2017-04-13 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
US9609861B2 (en) 2011-05-17 2017-04-04 Velico Medical Inc. Platelet additive solution having a β-galactosidase inhibitor
AU2012255137A1 (en) 2011-05-17 2013-12-12 The Brigham And Women's Hospital, Inc. Improved platelet storage using a sialidase inhibitor
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
US20150365084A1 (en) * 2014-06-13 2015-12-17 Infineon Technologies Austria Ag Circuits and methods for operating a circuit

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
SU328634A1 (ru) 1971-01-05 1978-01-05 Butyrin V G Устройство дл забора проб крови у животных
SU938739A3 (ru) 1977-01-19 1982-06-23 Мицубиси Кемикал Индастриз Лимитед(Фирма) Способ получени N -арилсульфонил-L-аргининамидов или их солей
US4418052A (en) * 1980-08-12 1983-11-29 Wong Dennis W Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5024829A (en) * 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
GB9318637D0 (en) 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5656645A (en) * 1994-12-13 1997-08-12 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
NZ298699A (en) * 1994-12-13 2001-03-30 Corvas Int Inc 3-amino-1,2-dihydropyrid-1-yl(and 5-amino-1,6-dihydro-6-oxo(and 5,6-dioxo)pyrimidin-1-yl)-acetyl-argininal derivatives, useful for the treatment of blood coagulation and thrombosis
US5658930A (en) * 1994-12-13 1997-08-19 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
JPH11508558A (ja) * 1995-06-27 1999-07-27 メルク エンド カンパニー インコーポレーテッド ピリジノン トロンビン阻害剤
JP2000512616A (ja) * 1996-02-22 2000-09-26 メルク エンド カンパニー インコーポレーテッド ピリジノントロンビンインヒビター
US5891909A (en) 1996-03-29 1999-04-06 3-Dimensional Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
AU751412B2 (en) * 1997-11-26 2002-08-15 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
DE69942159D1 (de) * 1998-06-11 2010-04-29 Ortho Mcneil Pharm Inc Pyrazine Protease Inhibitore
MXPA01011956A (es) 1999-05-27 2002-06-21 Dimensional Pharm Inc Oxazaheterociclos como inhibidores de proteasas.
DE60005351D1 (de) 1999-07-09 2003-10-23 Dimensional Pharm Inc Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel
US6236492B1 (en) * 1999-08-03 2001-05-22 Crystal Corporation Electrode with a balanced centroid, soft edges and an apodization ratio greater than one

Also Published As

Publication number Publication date
AR016702A1 (es) 2001-07-25
US6472399B2 (en) 2002-10-29
US6350764B2 (en) 2002-02-26
EA200000578A1 (ru) 2001-02-26
JP2001524467A (ja) 2001-12-04
US20030225115A1 (en) 2003-12-04
DE69836346D1 (de) 2006-12-14
US20030087921A1 (en) 2003-05-08
BR9815325A (pt) 2001-12-26
EA004180B1 (ru) 2004-02-26
US20020007070A1 (en) 2002-01-17
AU1799199A (en) 1999-06-15
CA2311969A1 (en) 1999-06-03
US20020086872A1 (en) 2002-07-04
TWI222441B (en) 2004-10-21
AU751412B2 (en) 2002-08-15
US6245763B1 (en) 2001-06-12
US6037356A (en) 2000-03-14
WO1999026926A1 (en) 1999-06-03
ATE344246T1 (de) 2006-11-15
EP1036063B1 (en) 2006-11-02
EP1036063A1 (en) 2000-09-20
US20060211719A1 (en) 2006-09-21
US7402586B2 (en) 2008-07-22
US7029654B2 (en) 2006-04-18
US6566379B1 (en) 2003-05-20
US20040106633A1 (en) 2004-06-03
ES2274587T3 (es) 2007-05-16
US6706021B2 (en) 2004-03-16
PL340560A1 (en) 2001-02-12

Similar Documents

Publication Publication Date Title
DE69836346T2 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE60122546T2 (de) Aminopyridinyl-, aminoguanidinyl- und alkoxyguanidinyl- substituierte phenylacetamide als protease inhibitoren
EP1086122B1 (en) Pyrazinone protease inhibitors
DE69637307T2 (de) Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
DE69631692T2 (de) Amidino proteaseinhibitoren
US6326492B1 (en) Heterocyclic protease inhibitors
US6420397B1 (en) Heteroaryl protease inhibitors and diagnostic imaging agents
DE60006407T2 (de) Azazykloalkanone serin-protease-hemmer
JP2006522809A (ja) 置換フェニルアセトアミおよびプロテアーゼインヒビターとしてのその使用
MXPA00005055A (en) Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
DE60204800T2 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose
MXPA00011612A (en) Pyrazinone protease inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee